Dr Reddy's Rituximab Biosimilar to Undergo Clinical Trial in South Korea, an Industrial Info Market Brief
Dr Reddy's Rituximab Biosimilar to Undergo Clinical Trial in South Korea, an Industrial Info Market Brief
Attachment: Dr Reddy 0919
Dr. Reddy's Laboratories, India's leading pharmaceutical manufacturer, received approval earlier this month from South Korea's Ministry of Food and Drug Safety to undertake the third-phase clinical trial of its Rituximab biosimilar of Roche's MabThera in South Korea.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021